Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RM-1995 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Rakuten Medical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Photoactivation (pit Is Administered Systemically And Then Activated Locally By Light)
01
Overview
RM-1995 + pembrolizumab is an experimental combination therapy under investigation for cancer, combining RM-1995 photoimmunotherapy (PIT) with pembrolizumab, a programmed cell death 1 (PD-1) immune checkpoint inhibitor. RM-1995 is a photosensitive biologic administered to target tumor cells, which, upon activation by directed light, induces rapid tumor cell destruction and immunogenic cell death. Pembrolizumab binds to the PD-1 receptor on T-cells, blocking interaction with its ligands (PD-L1/PD-L2), thereby enhancing T-cell-mediated immune responses against cancer cells. The combination is being studied to evaluate safety, tolerability, and preliminary efficacy in solid tumors, including cutaneous squamous cell carcinoma[1][3].
- Other names
- pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on RM-1995 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RM-1995 + pembrolizumab.